Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOFOL vs DIPRIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in the ICU,Procedural sedation (e.g., during diagnostic or therapeutic procedures),Treatment of refractory status epilepticus (off-label),Management of severe agitation or delirium (off-label)
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in intensive care units,Monitored anesthesia care (MAC) sedation,Treatment of refractory status epilepticus (off-label),Procedural sedation (off-label)
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Primarily hepatic via conjugation to glucuronide and sulfate; also metabolized by CYP2B6 and CYP2C9. Metabolites are renally excreted.
Primarily hepatic conjugation to inactive metabolites (propofol glucuronide), with minor metabolism via CYP2B6 and CYP2C9 to 4-hydroxypropofol.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
95-99% bound primarily to albumin (≈48%) and alpha-1-acid glycoprotein (≈50%), with minor binding to lipoproteins.
95-99% bound, primarily to albumin.
Initial Vd: 0.2-0.4 L/kg (central compartment); steady-state Vd: 2-10 L/kg (extensive tissue distribution).
2-10 L/kg (large Vd indicating extensive tissue distribution).
IV: 100%; enteral: negligible due to first-pass metabolism; oral bioavailability <1%.
Intravenous: 100%; not available orally due to extensive first-pass metabolism.
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, use with caution due to propylene glycol accumulation, monitor for metabolic acidosis.
No adjustment required; propofol is not significantly renally eliminated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce by 75% due to prolonged clearance and risk of hypotension.
No specific Child-Pugh based guidelines; use lower doses due to impaired clearance, especially in cirrhosis.
Induction: 2.5-3.5 mg/kg IV over 30 sec. Maintenance: 125-300 mcg/kg/min for age <3 years; 100-200 mcg/kg/min for age 3-12 years. For sedation: 25-100 mcg/kg/min.
Induction: 2.5-3.5 mg/kg IV bolus; maintenance: 125-300 mcg/kg/min IV infusion. Not approved for ICU sedation in <16 years.
Reduce induction dose to 1-1.5 mg/kg IV; decrease infusion rate by 20-50% due to reduced clearance and increased sensitivity.
Reduce induction dose to 1-1.5 mg/kg IV bolus and maintenance infusion to 20-50 mcg/kg/min IV due to increased sensitivity and decreased clearance.
No FDA black box warnings.
Propofol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Patients should be continuously monitored for early signs of hypotension, bradycardia, apnea, airway obstruction, and oxygen desaturation. For sedation of intubated, mechanically ventilated patients in the ICU, propofol should be used with caution in patients with increased intracranial pressure or impaired cerebral circulation.
Hypotension and bradycardia: may require fluid resuscitation or vasopressors,Respiratory depression and apnea: must have airway management equipment available,Propofol infusion syndrome (PRIS): rare but fatal with high doses >4 mg/kg/hr for >48 hours; characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure,Risk of pancreatitis: monitor lipase if symptoms develop,Abrupt discontinuation may cause withdrawal symptoms after prolonged use,Not recommended for use in patients with propofol allergy or egg/soybean oil hypersensitivity (formulation contains egg lecithin and soybean oil)
Risk of hypotension and bradycardia, especially in elderly or hypovolemic patients,Respiratory depression and apnea requiring airway management,Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, renal failure, cardiac failure, especially with prolonged high-dose infusions,Hypertriglyceridemia; monitor lipids with prolonged use,Risk of pancreatitis,Use with caution in patients with epilepsy; may increase seizure risk during withdrawal,May cause green discoloration of urine, hair, or nails
Hypersensitivity to propofol or any component of the formulation (including egg lecithin, soybean oil, or disodium edetate),Patients with severe lipid metabolism disorders (e.g., pancreatitis with hypertriglyceridemia),Not for use in general anesthesia in obstetrics (crosses placenta; may cause neonatal depression),Relative: hypovolemia, hemodynamic instability, increased intracranial pressure (use with caution)
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, egg products, soybeans, or soy products (due to lipid vehicle),Patients with severe lipid metabolism disorders (e.g., hyperlipidemia),Not recommended for general anesthesia in patients with increased intracranial pressure or impaired cerebral circulation unless benefits outweigh risks
No specific food restrictions. However, propofol is formulated in a lipid emulsion containing soybean oil and egg lecithin, which may interact with high-fat meals theoretically but not clinically significant. Avoid alcohol for 24 hours post-procedure due to additive sedative effects.
No specific food interactions; however, propofol emulsion contains soybean oil and egg lecithin, so avoid in patients with egg or soy allergies. The emulsion can be contaminated if bottle is reused; discard after single use. No dietary restrictions required for administration.
First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second trimester: No clear evidence of fetal harm. Third trimester: Use may cause neonatal respiratory depression, hypotonia, and neurobehavioral effects; risk of fetal bradycardia and hypoxia. Propofol crosses the placenta rapidly.
Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third trimesters, propofol crosses the placenta and may cause neonatal respiratory depression and neurobehavioral depression. Risk of fetal acidosis and bradycardia. No major teratogenic effects reported in human studies, but limited data.
Propofol is excreted into breast milk in very low concentrations, with an estimated M/P ratio of 1.2-1.5. The relative infant dose is <0.1% of weight-adjusted maternal dose. Consider discarding milk for 24 hours after administration due to potential sedative effects on the infant.
Propofol is excreted into breast milk in low concentrations. M/P ratio not established. Due to low oral bioavailability, risk to infant is minimal. However, caution is advised due to potential CNS depression in neonates. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration.
Pregnancy increases volume of distribution and clearance of propofol by 20-50%, primarily due to increased cardiac output and hepatic blood flow. Induction doses may need to be increased by 15-30% to achieve desired effect. Maintenance infusion rates may also require upward titration.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, particularly in the third trimester. No specific dose adjustment guidelines; clinical response and patient condition determine dosing. Reduced doses may be required due to increased sensitivity to propofol in pregnancy.
Propofol causes dose-dependent respiratory depression and apnea; always have airway equipment ready. It reduces cerebral metabolic rate and intracranial pressure, making it useful for neuroanesthesia. Pain on injection is common, particularly in small veins; consider lidocaine pretreatment. Propofol infusion syndrome (PRIS) is a rare but fatal complication with prolonged high-dose infusions (>48h, >4 mg/kg/h), characterized by lactic acidosis, rhabdomyolysis, and cardiac failure. Avoid in patients with egg or soy allergy due to lipid emulsion. Use the lower dose for elderly or hemodynamically unstable patients. Monitor triglyceride levels with prolonged use.
DIPRIVAN (propofol) causes pain on injection, especially in small veins; pretreatment with lidocaine or use of a larger vein can mitigate. It is formulated as a lipid emulsion containing soybean oil and egg lecithin, thus contraindicated in patients with egg or soybean allergies. Propofol can cause profound hypotension and respiratory depression; ensure airway equipment and vasopressors are immediately available. The infusion syndrome (PRIS) is rare but lethal, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; avoid prolonged high-dose infusions (>5 mg/kg/hr for >48 hours).
This medication will cause you to feel very sleepy and lose consciousness quickly.,You may experience a burning or stinging sensation at the injection site; this is common.,Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,You might feel groggy, dizzy, or have a headache after waking up.,Inform your doctor if you have any allergies, especially to eggs, soy, or peanuts.,If you will be receiving this medication for a prolonged period, your doctor will monitor your heart, kidneys, and blood tests.
You will be monitored continuously during and after administration due to risk of low blood pressure and slowed breathing.,You may feel a burning or stinging sensation at the injection site; inform your healthcare provider if it persists.,Do not drive or operate machinery for at least 24 hours after receiving propofol due to residual sedation.,Inform your medical team if you have allergies to eggs, soy, or sesame seeds.,Propofol is not intended for home use; it is only administered in a supervised medical setting.
"Propofol, a general anesthetic, may inhibit CYP2C8, the primary enzyme responsible for rosiglitazone metabolism, leading to decreased clearance and elevated plasma concentrations of rosiglitazone. This interaction can potentiate the hypoglycemic effects of rosiglitazone, increasing the risk of hypoglycemia. Clinical vigilance is warranted when these agents are coadministered, especially in patients with diabetes."
"The combination of propofol and methyldopa can lead to an increased risk of severe hypotension and bradycardia due to additive cardiovascular depressant effects. Propofol causes peripheral vasodilation and direct myocardial depression, while methyldopa reduces sympathetic outflow and depletes catecholamines, enhancing propofol's hemodynamic effects. This interaction may result in profound hypotension, reduced cardiac output, and risk of organ hypoperfusion during anesthesia induction and maintenance."
"Propofol, a GABA-A receptor agonist and general anesthetic, depresses myocardial contractility and reduces systemic vascular resistance, leading to hypotension and bradycardia. Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, can blunt the compensatory tachycardia in response to propofol-induced vasodilation and myocardial depression. Concurrent use may result in additive negative chronotropic and inotropic effects, potentially causing severe bradycardia, hypotension, or reduced cardiac output, especially in patients with compromised cardiac function or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPOFOL vs DIPRIVAN, answered by our medical review team.
PROPOFOL is a General Anesthetic that works by Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.. DIPRIVAN is a General Anesthetic that works by Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPOFOL and DIPRIVAN depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPOFOL is: Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.. The standard adult dose of DIPRIVAN is: Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPOFOL and DIPRIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPOFOL is classified as Category A/B. First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second tr. DIPRIVAN is classified as Category C. Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.